Detail akcie Levrett online

Business Summary: Nuformix plc is a United Kingdom-based pharmaceutical development company, which is engaged in targeting unmet medical needs in fibrosis and oncology via drug repurpose. The Company aims to use its expertise in discovering, developing, and patenting novel drug forms, with improved physical properties, to develop new products that are differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Its pipeline includes NXP001, NXP002 and NXP004. NXP001 is a form of the drug aprepitant that is marketed as a product in the oncology supportive care setting. NXP002 is its pre-clinical lead asset and a potential inhaled treatment for idiopathic pulmonary fibrosis. NXP004 is a form of Olaparib, which is used for the treatment of adults with advanced ovarian cancer and deleterious or suspected deleterious germline BRCA mutation and has since secured similar approvals in breast, pancreatic and prostate cancers.
Financial Summary: BRIEF: For the six months ended 31 March 2026, Nuformix PLC revenues was not reported. Net loss decreased 8% to L347K. Lower net loss reflects Administrative expenses decrease of 8% to L347K (expense).